Nanologica AB (publ) (NICA.ST)
SEK 1.71
(-0.58%)
SEK 1.71
(-0.58%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 79.32 Million SEK | -2.49% |
| 2022 | 81.35 Million SEK | 74.13% |
| 2021 | 46.72 Million SEK | -12.48% |
| 2020 | 53.38 Million SEK | 39.87% |
| 2019 | 38.16 Million SEK | 259.34% |
| 2018 | 10.62 Million SEK | -55.7% |
| 2017 | 23.97 Million SEK | 143.71% |
| 2016 | 9.83 Million SEK | 14.02% |
| 2015 | 8.62 Million SEK | -24.54% |
| 2014 | 11.43 Million SEK | 252.85% |
| 2013 | 3.24 Million SEK | 20.11% |
| 2012 | 2.69 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 97.05 Million SEK | 22.35% |
| 2024 Q2 | 91.76 Million SEK | -5.45% |
| 2023 Q1 | 85.73 Million SEK | 5.38% |
| 2023 Q3 | 76.25 Million SEK | -2.2% |
| 2023 Q2 | 77.96 Million SEK | -9.06% |
| 2023 Q4 | 79.32 Million SEK | 4.03% |
| 2023 FY | 79.32 Million SEK | -2.49% |
| 2022 Q1 | 54.7 Million SEK | 17.1% |
| 2022 Q4 | 81.35 Million SEK | -1.08% |
| 2022 FY | 81.35 Million SEK | 74.13% |
| 2022 Q3 | 82.24 Million SEK | -10.45% |
| 2022 Q2 | 91.84 Million SEK | 67.88% |
| 2021 Q1 | 53.44 Million SEK | 0.11% |
| 2021 Q4 | 46.72 Million SEK | -4.18% |
| 2021 Q3 | 48.75 Million SEK | -6.11% |
| 2021 FY | 46.72 Million SEK | -12.48% |
| 2021 Q2 | 51.93 Million SEK | -2.83% |
| 2020 Q4 | 53.38 Million SEK | 21.74% |
| 2020 Q3 | 43.84 Million SEK | -12.47% |
| 2020 Q2 | 50.09 Million SEK | 2.3% |
| 2020 FY | 53.38 Million SEK | 39.87% |
| 2020 Q1 | 48.96 Million SEK | 28.31% |
| 2019 Q3 | 32.27 Million SEK | 308.07% |
| 2019 FY | 38.16 Million SEK | 259.34% |
| 2019 Q4 | 38.16 Million SEK | 18.24% |
| 2019 Q2 | 7.91 Million SEK | -24.57% |
| 2019 Q1 | 10.48 Million SEK | -1.27% |
| 2018 Q4 | 10.62 Million SEK | 12.74% |
| 2018 FY | 10.62 Million SEK | -55.7% |
| 2018 Q3 | 9.42 Million SEK | 2.75% |
| 2018 Q2 | 9.16 Million SEK | -59.97% |
| 2018 Q1 | 22.9 Million SEK | -4.46% |
| 2017 FY | 23.97 Million SEK | 143.71% |
| 2017 Q1 | 8.56 Million SEK | -12.99% |
| 2017 Q4 | 23.97 Million SEK | 51.39% |
| 2017 Q2 | 16.79 Million SEK | 96.23% |
| 2017 Q3 | 15.83 Million SEK | -5.72% |
| 2016 Q2 | 11.96 Million SEK | 56.41% |
| 2016 Q3 | 12.5 Million SEK | 4.51% |
| 2016 FY | 9.83 Million SEK | 14.02% |
| 2016 Q1 | 7.65 Million SEK | -11.33% |
| 2016 Q4 | 9.83 Million SEK | -21.34% |
| 2015 Q4 | 8.62 Million SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q2 | 10.18 Million SEK | 0.0% |
| 2015 FY | 8.62 Million SEK | -24.54% |
| 2014 FY | 11.43 Million SEK | 252.85% |
| 2014 Q3 | 11.43 Million SEK | 0.0% |
| 2014 Q4 | 11.43 Million SEK | 0.0% |
| 2013 FY | 3.24 Million SEK | 20.11% |
| 2012 FY | 2.69 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 25.581% |
| Ziccum AB (publ) | 6.38 Million SEK | -1141.813% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -3262.738% |
| BioArctic AB (publ) | 139.5 Million SEK | 43.136% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -129.249% |
| Mendus AB (publ) | 51.22 Million SEK | -54.86% |
| Genovis AB (publ.) | 98.04 Million SEK | 19.093% |
| Intervacc AB (publ) | 21.68 Million SEK | -265.899% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -197.016% |
| Active Biotech AB (publ) | 13.4 Million SEK | -491.993% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 36.016% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -392.195% |
| Aptahem AB (publ) | 8.99 Million SEK | -781.624% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -94.148% |
| Kancera AB (publ) | 17.97 Million SEK | -341.245% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -71.778% |
| Fluicell AB (publ) | 8.91 Million SEK | -789.815% |
| Saniona AB (publ) | 86.08 Million SEK | 7.848% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1437.941% |
| Biovica International AB (publ) | 34.76 Million SEK | -128.168% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -579.868% |
| AcouSort AB (publ) | 10.37 Million SEK | -664.377% |
| Xintela AB (publ) | 14.01 Million SEK | -466.015% |
| Abliva AB (publ) | 16.78 Million SEK | -372.719% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 63.035% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -585.686% |
| OncoZenge AB (publ) | 1.69 Million SEK | -4569.041% |
| Amniotics AB (publ) | 10.54 Million SEK | -652.129% |
| 2cureX AB (publ) | 2.93 Million SEK | -2602.794% |
| CombiGene AB (publ) | 4.15 Million SEK | -1808.735% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1692.296% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 94.934% |
| Camurus AB (publ) | 414.81 Million SEK | 80.877% |
| Corline Biomedical AB | 6.78 Million SEK | -1068.464% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -29.288% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -313.938% |
| I-Tech AB | 16.2 Million SEK | -389.522% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 93.311% |
| Cyxone AB (publ) | 4.69 Million SEK | -1589.966% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -495.191% |
| Biosergen AB | 5.08 Million SEK | -1460.02% |
| Cantargia AB (publ) | 54.97 Million SEK | -44.31% |
| NextCell Pharma AB | 13.68 Million SEK | -479.492% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -10.406% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -476.02% |
| SynAct Pharma AB | 51.83 Million SEK | -53.04% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -897.949% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1427.004% |
| LIDDS AB (publ) | 3.75 Million SEK | -2012.007% |
| Lipum AB (publ) | 7.53 Million SEK | -952.361% |
| BioInvent International AB (publ) | 90.45 Million SEK | 12.3% |
| Alzinova AB (publ) | 9.33 Million SEK | -750.145% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 56.317% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -4321.795% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -328.934% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1966.884% |
| Simris Alg AB (publ) | 148.93 Million SEK | 46.738% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -11.543% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 83.548% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -522.465% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -992.658% |